Genome-wide Studies of Verbal Declarative Memory in Nondemented Older People: The Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium by Debette, Stéphanie et al.
Genome-wide Studies of Verbal Declarative Memory in 
Nondemented Older People: The Cohorts for Heart and Aging 
Research in Genomic Epidemiology Consortium
A full list of authors and affiliations appears at the end of the article.
Abstract
BACKGROUND—Memory performance in older persons can reflect genetic influences on 
cognitive function and dementing processes. We aimed to identify genetic contributions to verbal 
declarative memory in a community setting.
METHODS—We conducted genome-wide association studies for paragraph or word list delayed 
recall in 19 cohorts from the Cohorts for Heart and Aging Research in Genomic Epidemiology 
consortium, comprising 29,076 dementia-and stroke-free individuals of European descent, aged 
≥45 years. Replication of suggestive associations (p < 5 × 10−6) was sought in 10,617 participants 
of European descent, 3811 African-Americans, and 1561 young adults.
RESULTS—rs4420638, near APOE, was associated with poorer delayed recall performance in 
discovery (p = 5.57 × 10−10) and replication cohorts (p = 5.65 × 10−8). This association was 
stronger for paragraph than word list delayed recall and in the oldest persons. Two associations 
with specific tests, in subsets of the total sample, reached genome-wide significance in combined 
analyses of discovery and replication (rs11074779 [HS3ST4], p = 3.11 × 10−8, and rs6813517 
[SPOCK3], p = 2.58 × 10−8) near genes involved in immune response. A genetic score combining 
58 independent suggestive memory risk variants was associated with increasing Alzheimer disease 
pathology in 725 autopsy samples. Association of memory risk loci with gene expression in 138 
human hippocampus samples showed cis-associations with WDR48 and CLDN5, both related to 
ubiquitin metabolism.
CONCLUSIONS—This largest study to date exploring the genetics of memory function in ~ 
40,000 older individuals revealed genome-wide associations and suggested an involvement of 
immune and ubiquitin pathways.
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The ability to form and retrieve memories is one of the most fundamental and complex 
aspects of human cognition. Decline in memory performance is a prominent marker of 
cognitive decline that occurs in late life and is one of the earliest signs of dementia (1,2). 
Verbal declarative memory, the conscious recall of information that can be retrieved 
verbally, can be measured using word list and paragraph recall tests. The delayed recall 
performance of these tests is a powerful predictor of Alzheimer disease (AD) (3).
Cognitive ability and memory performance were shown to be highly heritable (4–7). 
However, few consistent genetic associations have been described, mostly assessed by 
candidate gene association studies (8,9). Three genome-wide association studies (GWAS) of 
verbal declarative memory, on overlapping samples of 333 to 1073 young adults in their 
twenties, have identified associations of genetic variants in the KIBRA and CTNNBL1 genes 
with delayed recall (10,11). No GWAS of verbal declarative memory delayed recall 
performance has been performed in older individuals to our knowledge.
Genetic determinants of verbal declarative memory are likely to differ between young and 
old individuals, although some may be shared across age groups (4). In young adults, 
developmental genes determining the neural networks required for learning, storage, and 
retrieval or genes involved in the molecular mechanisms of memory storage (12) could be 
expected to harbor most susceptibility variants. In older individuals, variants in genes 
involved in brain aging and neurodegenerative disease may be more likely revealed (13).
Our aim was to identify genetic variants associated with memory performance in late 
middle-aged and older individuals. We conducted a meta-analysis of GWAS for delayed 
recall performance in tests of verbal declarative memory in 29,076 older community-based 
individuals and sought replication and extension of findings in 13,998 independent older 




Analyses were performed in 19 population-based cohorts participating in the Cohorts for 
Heart and Aging Research in Genomic Epidemiology consortium (Section 2, Table S1 in 
Supplement 1). All subjects were aged ≥45 years and dementia and stroke free at cognitive 
assessment. The study population comprised 29,076 participants of European ancestry, 
including 6674 participants with paragraph recall and 24,604 participants with word list 
recall tests. Each cohort secured approval from institutional review boards, and all 
participants provided written informed consent for study participation, cognitive testing, and 
use of DNA for genetic research. None of these studies have previously published GWAS 
for delayed recall performance in tests of verbal declarative memory.
Memory Tests
Participants were administered one or both types of verbal declarative memory tests: word 
list delayed recall (WL-dr) and paragraph delayed recall (PAR-dr). WL-dr comprised tests 
using visually or verbally presented word lists, with or without semantic relatedness between 
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the words; PAR-dr comprised tests using one or two verbally presented stories (Figure 1; 
Table S2 in Supplement 1). Participants were asked to remember as many words or 
paragraph elements as possible after a specified delay interval, preceded by an immediate 
recall task (Section 3 in Supplement 1). We decided a priori to run both global meta-
analyses combining all tests and meta-analyses combining similar tests. Indeed, different 
memory tests may involve partly distinct neural networks and mechanisms (Section 3 in 
Supplement 1). Meta-analyses thus comprised a combination of all measures of delayed 
recall (ALL-dr; n = 29,076), PAR-dr (n = 6674), WL-dr (n = 24,604), and various subtypes 
of WL-dr tests, including Consortium to Establish a Registry for Alzheimer’s Disease 
delayed recall (CERAD-dr, n = 4,274), Delayed Word Recall Test (n = 9,188), Rey 
Auditory Verbal Learning Test (RAVLT-dr, n = 4,274), California Verbal Learning Test 
(CVLT-dr, n = 2,950), and Hopkins Verbal Learning Test (n = 331) (Figure 1).
Genotyping and Imputation
The consortium was formed after the individual studies had finalized their GWAS 
platforms; hence, the studies included used different platforms. Genotyping platforms are 
described in Table S4 in Supplement 1. Imputation to nonmonomorphic, autosomal single 
nucleotide polymorphisms (SNPs) from the HapMap CEU (Utah residents with Northern 
and Western European ancestry from the CEPH collection) panel was performed with 
standard quality control filters (Section 4, Tables S5 and S6 in Supplement 1). APOE-ε 
genotypes are not available on the GWAS arrays; however, APOEε had been genotyped 
separately in most cohorts.
Discovery GWAS
Within each cohort, a linear regression model was used to evaluate the association of raw 
scores for delayed recall (number of words or story elements recalled) with the number of 
minor alleles (0 to 2) at each SNP. Analyses were adjusted for age and sex and, if relevant, 
study site, familial structure, and population substructure (Section 5 in Supplement 1). We 
additionally adjusted for educational achievement (Table S1 in Supplement 1) in a 
secondary model only, as this could weaken associations with developmental genes that may 
impact educational attainment.
We undertook meta-analyses with METAL (14) using inverse-variance weighted meta-
analysis to combine GWAS for the same memory test and effective sample size weighted 
meta-analysis to combine GWAS for nonidentical memory tests (Section 5 in Supplement 
1). Effective sample size weighted meta-analysis is recommended when the dependent 
variable is measured on different scales between cohorts and does not yield any directly 
comparable effect estimate. For each SNP, the Z statistic was weighted by the effective 
sample size (product of the sample size and the ratio of the empirically observed dosage 
variance to the expected binomial dosage variance for imputed SNPs). A combined estimate 
was obtained by summing the weighted Z statistics and dividing by the summed weights. 
Genomic control was used to remove residual population stratification within cohorts and in 
the meta-analysis.
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We sought to replicate our strongest association signals (p < 5 × 10−6) in seven independent 
population-based cohorts including 10,617 participants of European descent. We also 
attempted to extend our findings to 3811 individuals of African-American ancestry and to 
1561 young adults in their twenties (Section 2, Table S1 in Supplement 1; for genotyping 
methods, Section 4, Tables S4–S6 in Supplement 1).
Functional Annotation
Expression Quantitative Trait Loci—We analyzed the association of suggestive 
memory risk loci from the discovery GWAS (p < 5 × 10−6) with hippocampus cell line 
whole-genome gene expression profiles. This information was derived from 138 human 
premortem hippocampus samples (15). Exploratory p value thresholds of .05 were used for 
cis-expression quantitative trait loci (eQTL) (distance between SNP and probe < 2 Mb) and 
10−4 for trans-eQTLs (Section 6 in Supplement 1).
Pathway Analysis—Pathway analyses were carried out using the core analysis function 
of the Ingenuity Pathway Analysis software (IPA; Ingenuity Systems, Redwood City, 
California). We performed gene-based tests for association based on results from the PAR-
dr and WL-dr discovery GWAS, using the Versatile Gene-based Association Study 
(VEGAS) software (16). The full list of genes and gene-based p values generated by 
VEGAS was uploaded into IPA for use as a reference set (16,965 genes were available for 
the PAR-dr analysis and 16,953 for the WL-dr analysis). From this list, p value cutoffs of .
01 or .05 were used to identify IPA focus molecules (Section 7 in Supplement 1). Networks 
generated by IPA provide insight into the molecular interactions of the focus molecules, 
independent of any predictions of biological function. For this analysis only, direct 
interactions were used, that is, where there is physical contact between the two molecules. 
The network building algorithm ranks focus molecules by interconnectedness (the number 
of triangular connections with other pairs of genes). The top molecule is taken as a seed 
gene and additional focus molecules are added, prioritizing those that have the most overlap 
with the existing network. The default IPA network size of 35 nodes was used (Section 7 in 
Supplement 1).
Association with AD Pathology
We examined the relation of memory risk alleles and a memory genetic score with AD 
pathology (intracellular neurofibrillary tangles and extracellular amyloid plaques) in the 
Religious Orders Study and the Rush Memory and Aging Project (n = 725; Section 8 in 
Supplement 1) (17). The memory genetic score comprised all independent SNPs (R2 < .25) 
associated with memory performance at p < 5 × 10−6 (Section 9 in Supplement 1). Briefly, 
each participant was assigned a score value, determined by summing up the number of 
copies (or imputed dosage) of each memory risk allele; each SNP in the score was weighted 
by the corresponding Z score from the memory GWAS meta-analysis.
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APOE Locus—Because APOEε4 is the major known genetic risk factor for AD, we 
explored its association with memory performance in discovery and replication studies 
where this genotype was available (n = 33,403 for WL-dr, n = 13,170 for PAR-dr), 
comparing APOEε4 carriers with noncarriers. Secondary analyses stratified on the cohort’s 
mean age (≥ 65 versus < 65) were run.
Published Memory and AD Risk Alleles—In the discovery GWAS, we tested whether 
memory performance was associated with published memory susceptibility SNPs and 
confirmed AD risk variants other than APOEε4; Bonferroni correction for the number of 
independent SNPs (R2 < .25) (18) tested was used, corresponding to significance thresholds 
of p < .0029 (= .05/17) for memory risk variants and p < .0025 (= .05/20) for AD risk 
variants available in HapMap (Tables S11 and S12 in Supplement 2). For published memory 
risk variants, we extracted gene-based p values [obtained with VEGAS (16)] for genes 
closest to these variant SNPs (p threshold < .0036 [.05/14 genes]). We also constructed a 
genetic risk score comprising AD risk variants from 20 independent AD risk loci (19) to 
estimate the joint effect of these SNPs on memory performance (Section 10 in Supplement 
1) (20).
RESULTS
GWAS of Verbal Declarative Memory
GWAS meta-analyses of verbal declarative memory comprised in total 29,076 participants 
(mean age 63.6 ± 7.0 years, 56.0% women; see Table S1 in Supplement 1 for detailed 
demographic characteristics). Quantile-quantile plots showed no evidence of spurious 
inflation of p values or significant population stratification (Figure S1 in Supplement 1). 
Genome-wide plots of p values for SNPs against their genomic position are shown in Figure 
S2 in Supplement 1. For replication, 10,617 participants (72.8 ± 5.4 years, 78.3% women) 
were available.
Two loci reached genome-wide significance (Tables 1 and 2): on chromosome 19q12 
(rs4420638, p = 1.94 × 10−10) with PAR-dr and on chromosome 5q11 (rs13358049, p = 9.69 
× 10−9) with CVLT-dr. The top SNPs on chromosome 19q12 are in linkage disequilibrium 
(LD) with APOEε4 and are known to be associated with an increased risk of AD. They were 
significantly replicated (p = 5.65 × 10−8 for rs4420638). In the combined discovery and 
replication sample, rs4420638 explained approximately 1% of the variance in paragraph 
delayed recall performance (Table S13 in Supplement 1). Although the direction of effect 
was consistent, the chromosome 5q11 locus was not confirmed in the replication sample.
In total, 174 SNPs reached a suggestive p value (p < 5 × 10−6) in at least one GWAS meta-
analysis (Table S7 in Supplement 2), representing 58 independent loci (R2 < .25). The 
association between RAVLT-dr and rs11074779 (chromosome 16p12, near HS3ST4) was 
replicated (p = 1.08 × 10−3) and reached genome-wide significance when combining 
discovery and replication cohorts (p = 3.11 × 10−8; Figure 2, Table 3). Association of 
CERAD-dr with rs6813517 (chromosome 4q32.3, near SPOCK3) was significant in an 
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African-American extension sample (p = .020) and reached genome-wide significance when 
combining with the discovery GWAS (p = 2.58 × 10−8; Figure 2, Table 4). No European 
replication sample was available for CERAD-dr. Three additional SNPs were replicated at p 
< .05 with effects in the same direction, without reaching genome-wide significance (Tables 
1 and 2): rs9528384 (chromosome 13q21), rs1633735 (chromosome 5p15) with PAR-dr, 
and rs13166268 (chromosome 5q23) with CVLT-dr.
The above findings were not significant in a sample of 1561 young adults (22.3 ± 3.4 years, 
69.1% women; Table S7 in Supplement 2).
APOE and Delayed Recall Performance
The APOE locus (i.e., APOEε4 and GWAS SNPs in LD) yielded genome-wide significant 
associations with PAR-dr, while associations with WL-dr were much less significant (p > 5 
× 10−6), despite a larger sample size (Tables 1 and 5). When restricting analyses to older 
cohorts (mean age ≥65), associations of APOEε4 with memory performance were 
significantly strengthened (p = 1.22 × 10−5 and p = 2.64 × 10−3 for difference with WL-dr 
and PAR-dr in young cohorts), still reaching weaker significance levels for WL-dr (p = 6.25 
× 10−11) than for PAR-dr (p = 3.84 × 10−20). This remained true when restricting analyses to 
studies where the same participants underwent both tests of WL-dr (p = 1.34 × 10−17) and 
PAR-dr (p = 6.80 × 10−7). Associations of APOEε4 with memory performance were 
substantially weakened after adjustment for the most significant GWAS proxy (rs4420638), 
suggesting no additional independent signal at this locus (Table 5). There was a nominally 
significant interaction of APOEε4 carrier status with rs11074779 in association with 
RAVLT (p = .02) but not with other SNPs reaching genome-wide significance in the GWAS 
or in the combined analysis of discovery and follow-up cohorts; APOEε4 non-carriers had 
slightly higher effect estimates for the association of rs11074779 with RAVLT compared 
with APOEε4 carriers (Table S8 in Supplement 1).
Functional Annotation
Hippocampal eQTL—Among associations of suggestive memory risk variants with RNA 
expression in the human hippocampus (Table S9 in Supplement 2), the most significant cis-
associations included rs2280630 (PAR-dr, p[eQTL] = 6.59 × 10−7) with WDR48, encoding a 
ubiquitin-specific protease associated protein belonging to a family of deubiquitinating 
enzymes, and rs5747035 (RAVLT-dr, p[eQTL] = 7.63 × 10−3) with CLDN5, encoding a 
membranal tight junction protein that plays a critical role in determining the permeability of 
endothelial barriers and whose degradation is regulated by the ubiquitin-proteasome 
pathway (21). Associations of rs2280630 and rs5747035 with PAR-dr and RAVLT-dr were 
in the same direction as in the discovery GWAS in the follow-up studies but did not reach 
significance (p = .058 and .19; Tables 1 and 3).
Pathway Analysis—The networks reaching the highest score, i.e., the lowest chance of 
randomly finding the selected number of focus molecules in a network of the selected size, 
are shown in Figure S3 in Supplement 1. In the PAR-dr pathway analysis using a gene-
based p value cutoff of .01, the top three networks and networks 5 and 6 (ordered by 
decreasing scores, respectively, of 33, 28, 26, 25, 24, 21) all included Ubiquitin C (UBC) as 
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a central hub. UBC was also a central hub in networks 3, 4, 5, and 6 (respective scores 27, 
26, 23, and 23) of the WL-dr pathway analysis using a gene-based p value cutoff of .01. 
When using a gene-based p value cutoff of .05, several PAR-dr and WL-dr networks also 
included UBC as a central hub. As UBC has a large number (n = 8332) of directly related 
molecules, we calculated whether there are more UBC interactions in the whole focus 
molecule set than would be expected by chance, given the number of UBC interactions in 
the reference set, using the hypergeometric distribution test. The latter suggested that this 
over-representation was not due to chance (Table S10 in Supplement 1).
Association with AD Pathology
The APOE locus and four intronic SNPs in LD within the KIAA1797 gene on chromosome 9 
were associated with increasing amyloid plaque burden and neurofibrillary tangle density 
(false discovery rate-corrected p value < .05; Table S11 in Supplement 2). The memory 
genetic score, combining 58 independent variants associated with memory at p < 5 × 10−6, 
was significantly associated with increasing amyloid plaque burden (effect estimate [β] ± 
SE: .0103 ± .0045, p = .022) and neurofibrillary tangle density (β ± SE: .0106 ± .0035, p = .
0028). After removing the APOE locus from the score, the association was still significant 
for neurofibrillary tangle density (β ± SE: .0079 ± .0036, p = .027).
Candidate Gene Analysis
Published Memory Risk Variants—None of the SNPs previously reported to be 
associated with memory performance, mostly in young cohorts, reached a statistically 
significant level of association after correction for multiple testing in our middle-aged to 
older samples (Table S12 in Supplement 1).
Published Risk Variants for AD—Except for APOE, none of the AD risk loci were 
significantly associated with memory performance individually (Table S14 in Supplement 
1). However, an AD genetic risk score was significantly associated with worse performance 
on WL-dr, CERAD-dr, ALL-dr, and PAR-dr; the latter two associations remained 




In this first GWAS of verbal declarative memory in almost 30,000 older nondemented 
community adults, we observed a genome-wide significant association of the APOE locus 
with poorer memory performance, especially for paragraph delayed recall. Two additional 
associations in subsets of the total sample and for specific tests, i.e., of rs11074779 near 
HS3ST4 with RAVLT-dr and of rs6813517 near SPOCK3 with CERAD-dr, were replicated 
and reached genome-wide significance after combining discovery and replication samples.
Results were overall similar with and without education adjustment. Associations with the 
APOE locus tended to be slightly more significant in the education-adjusted model, whereas 
SNPs near genes involved in neuronal development and synaptic function were more 
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significantly associated without education adjustment, in line with the hypothesis that effects 
of developmental genes may be masked by correcting for educational achievement (22).
In the Context of the Literature and Putative Mechanisms
Although APOEε4 is a well-established risk factor for AD, its association with memory 
performance is controversial (9,23); some studies on relatively small samples have 
suggested an age-dependent detrimental effect of APOEε4 on memory performance (24) and 
even a protective effect in young adults (25). The present findings confirm a highly 
significant association of APOEε4 with poorer memory performance in the oldest cohorts, 
while the association did not reach or barely reached significance in the young and middle-
aged cohorts, both in European and African-American samples. Whereas this age-dependent 
effect could be partly ascribed to the higher prevalence of subclinical AD with increasing 
age, APOEε4 could also influence cognitive aging independently of the mechanisms 
underlying AD (13). The much stronger detrimental effect of APOEε4 on PAR-dr than on 
WL-dr is intriguing. Word list and story listening tasks were shown to activate different 
brain regions, with unequal involvement of the right hemisphere (26,27), and performance 
on these tests is significantly but not very strongly correlated (Table S3 in Supplement 1). 
Our data suggest that PAR-dr may perhaps better capture APOEε4-related decline in 
memory performance than WL-dr. More broadly, these discrepancies have important 
implications when planning future genetic studies of cognition as they highlight how distinct 
memory tasks are (even when focusing on delayed recall performance) and potentially also 
in the context of ongoing and proposed preventive trials for cognitive decline or dementia 
targeting APOEε4 carriers; our results suggest that paragraph delayed recall tests might be a 
more suitable end point for these studies (28).
Even after excluding APOE, AD genetic risk loci were associated, in aggregate, with poorer 
delayed recall performance. This may suggest that, even in nondemented older adults, 
diminished performance in verbal declarative memory may be partly mediated by early 
preclinical neurodegenerative processes. This was further supported by the association of the 
memory genetic score with a larger burden of AD pathology, which suggests that, in 
combination, memory risk loci distinct from the known AD risk loci also contribute to AD 
pathology. However, taken individually, apart from APOE, none of the memory risk variants 
reaching genome-wide significance in the combined discovery and replication sample were 
known AD risk variants or were associated with AD pathology, indicating that other 
mechanisms may be modulating memory performance in older dementia-free individuals.
We did not confirm previously reported associations with memory performance; however, 
previous studies were conducted mostly in young adults and did not focus exclusively on the 
delayed recall component of memory.
The association of rs11074779 with RAVLT-dr was replicated and reached genome-wide 
significance in the combined analysis of European discovery and replication samples. 
Rs11074779 is located at 302 kilobase from HS3ST4, which is strongly expressed in the 
hippocampus and is thought to play a role in herpes simplex virus (HSV)-1 pathogenesis 
(29); it is intriguing that HSV-1 infection of the brain (herpes simplex encephalitis) 
preferentially affects the hippocampus and can result in profound memory loss. Further, 
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AD-related plaques and tangles were shown to be enriched in HSV-1 binding proteins (30), 
and although controversial, a possible role of HSV-1 has been suggested in AD occurrence 
(31–33). The association of rs6813517 with CERAD-dr was significant in an African-
American extension cohort and reached genome-wide significance in the combined analysis 
of discovery and extension samples. Rs6813517 is located at 367 kilobase from SPOCK3, 
encoding a member of a novel family of calcium-binding proteoglycan proteins, which is 
strongly expressed in cerebral cortex and hippocampus. Another variant near SPOCK3 
(rs13111850, R2 = .003 with rs6813517) was recently found to be associated with variations 
in cytokine secretion in response to smallpox vaccine (34). Interestingly, an immune system 
dysfunction has been suggested in AD based on findings from recent AD GWAS and 
genome-wide pathway analyses (19,35–37). Functional prediction analyses using the Kyoto 
Encyclopedia of Genes and Genomes and Gene Ontology suggest that HS3ST4 is implicated 
in synaptic transmission and neurotransmitter receptor activity, while SPOCK3 appears to be 
involved in regulation of action potential in neurons, neurotransmitter uptake, and memory 
(http://genenetwork.nl). Two suggestive intergenic variants associated with PAR-dr (near 
protocadherin 20 [PCDH20] and semaphorin 5A [SEMA5A]) reached nominal significance 
in the replication analysis. PCDH20 belongs to the subfamily of nonclustered 
protocadherins, which likely contribute to the establishment and remodeling of selective 
synaptic connections and to the maintenance and plasticity of adult hippocampal circuitry 
(38). SEMA5A belongs to the semaphorin family, which is involved in axonal guidance 
during neural development (39) and has been associated with autism (40).
In the pathway analyses, a larger proportion of genes appeared to bind polyubiquitin C than 
predicted by chance, and several eQTL associations with genes involved in ubiquitin 
metabolism were observed. Converging evidence suggests a major role of impaired protein 
degradation by the ubiquitin proteasome system in neurodegenerative disorders including 
AD (41,42). Ubiquitination was also demonstrated to facilitate hippocampal plasticity and 
hippocampal-dependent memory storage by modulating CPEB3 activity and CPEB3-
dependent protein synthesis and synapse formation (43).
Strengths and Limitations
Strengths of this study include the large sample size and the diversity of populations studied. 
We provide a wide array of functional analyses including assessments of shared genetic 
variation with AD pathology and hippocampal gene expression analyses. The main 
limitation is the absence of replicated genome-wide significant findings in the discovery 
cohort apart from the APOE locus, despite the very large sample size and despite substantial 
heritability of verbal semantic memory delayed recall, with heritability estimates ranging 
between h2 = .30 and h2 = .52 (p < 1.20 × 10−4) in participating studies and in the literature 
(Section 11 in Supplement 1). Different tests have been performed across cohorts to quantify 
verbal memory performance: we attempted to harmonize tests by close examination of each 
test selected for inclusion and performed test-specific meta-analyses, although this implied 
smaller sample sizes, thereby reducing statistical power. This has likely reduced our ability 
to detect genetic associations and suggests that efforts should be made in the future to 
collectively define cognitive testing protocols across various large population-based 
samples. Age differences between discovery and follow-up studies may have reduced our 
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ability to replicate findings; sensitivity analyses performed in the discovery cohorts on the 
top loci showed that associations were slightly strengthened when focusing on a more 
narrow age range (Table S16 in Supplement 1). The absence of association of our top loci 
with memory performance in the extension cohort of young adults, although we had 
relatively limited power for this analysis (Table S16 in Supplement 1), also supports that 
genetic risk loci for memory performance may differ according to age.
The intrinsic complexity and heterogeneity of mechanisms influencing memory performance 
is a major challenge in deciphering the genetics of human verbal memory (28). Cognitive 
tests are influenced by medication, anxiety, and mood, inducing variance in the verbal 
memory phenotype that is not attributable to genetic variation, possibly hampering power to 
detect genetic susceptibility variants for memory performance (44). Moreover, effect sizes 
for quantitative traits are often small and may require larger sample sizes to be detected. As 
our aim was to identify genetic variants associated with memory performance in older 
community persons and not to study genetic determinants of memory performance in a 
selected sample of cognitively high-functioning individuals, we did not exclude participants 
in the low range of cognitive performance who may have been categorized as having mild 
cognitive impairment based on neuropsychological test results.
Conclusion and Implications
In conclusion, in a large sample of older community-dwelling adults, the APOE locus was 
associated with weaker verbal memory performance, especially in those above age 65 years. 
Two additional genome-wide associations, near HS3ST4 and SPOCK3, were identified and 
other putative modulators of memory performance were revealed by a pathway approach 
and hippocampal gene expression analyses, warranting further exploration in independent 
cohorts. The differential associations according to memory test characteristics and age 
should be accounted for in future studies. Finally, exploring other types of genetic variation, 
including rare variants and epigenetic modifications, will be crucial to decipher the full 
spectrum of memory heritability.
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Memory test categories and analysis strategy. Middle-aged (ma) cohorts aged >45 years, 
with an average age <65 years; old (o) cohorts aged >65 years; young (y) cohorts aged <45 
years. *in REasons for Geographic and Racial Differences in Stroke (REGARDS) the 
Consortium to Establish a Registry for Alzheimer’s Disease delayed recall (CERAD-dr) test 
was administered by phone.
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Regional association plots in the discovery genome-wide association study (GWAS) 
centered on rs11074779 (Rey Auditory Verbal Learning Test delayed recall [RAVLT-dr]) 
and rs6813517 (Consortium to Establish a Registry for Alzheimer’s Disease delayed recall 
[CERAD-dr]). Regional plot for associations in region centered on rs11074779 (RAVLT-dr) 
and rs6813517 (CERAD-dr), drawn using the LocusZoom software (45). All single 
nucleotide polymorphisms (SNPs) based on imputed results (dots) are plotted with their 
GWAS meta-analysis p values against their genomic position. The color of the dots 
represents the linkage disequilibrium between SNPs. Purple line represents estimated 
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recombination rates. Genes and exons are shown as dark blue arrows and vertical lines, 
respectively.
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